BSA modified, disulfide-bridged mesoporous silica with low biotoxicity for dual-responsive drug delivery

Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy

“…The major reason for selecting BSA was due to its immense bio-compatibility[ 20 , 21 ] and stabilizing capability [ 22 ]. Various biomedical applications including drug delivery [ [23] , [24] , [25] , [26] , [27] , [28] , [29] ], tissue engineering [ [30] , [31] , [32] , [33] ] and bio imaging, etc. extensively utilize BSA.…”

Recent Advances in pH- or/and Photo-Responsive Nanovehicles

“…The purpose of multi-stimuli-responsive nanovehicles is to achieve long circulation, high accumulation in targeted sites, deep penetration in targeted tissues such as tumors, internalization in targeted cells, endosome escape, and controlled drug release. [ 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 ]. In addition, multi-stimuli-responsive nanovehicles have been engineered to facilitate multistage drug delivery and achieve higher specificity and efficacy [ 157 ].…”

Tailored Mesoporous Inorganic Biomaterials: Assembly, Functionalization, and Drug Delivery Engineering

“…By contrast, specific chemicals, such as enzyme, cyclodextrins, carboxylates, DNA, glucose, glutathione, and so on, can be employed as efficient inductors to control the drug‐release dynamics, where these components can selectively release targeted drugs via redox process based on reductive–cleavable disulfide bonds. [ 7,34,85,97,124,140,156,172,236,237 ] In general, these chemicals possess low cytotoxicity, high biocompatibility, and abundant functional groups, which can protect drugs and maintain stability via strong bonding effects under healthy body fluids. Meanwhile, these gates will open to release targeted drugs under diseased tissue area based on the breakage of chemical bonds, which is induced by redox behavior under internal stimuli from therapy cell.…”

“…For drug delivery, despite artificial biomaterials exhibiting great potentials and intriguing features in various drug‐loaded engineering, especially for anticancer drugs and bone‐tissue regulation, single‐component mesoporous biomaterials are almost impossible to accomplish the whole delivery‐release task, which is limited by their inherent performance defects, including loading capacity, biocompatibility, stimuli sensitivity, and self‐degradation capacity. [ 79–82 ] Thus, these mesoporous biomaterials were usually modified to construct multicomponent nanocarriers with diverse techniques, such as polymer grafting, [ 26,83,84 ] bond bridging, [ 85–87 ] doping, [ 88,89 ] quantum dot capping, [ 90–93 ] and coating, [ 94–96 ] which can remarkably improve physicochemical properties of these biomaterials to realize drug therapy. In reality, traditional DDSs contain three indispensable segments.…”